BUSINESS

• Ono to Transfer 5 Established Injectable Brands to Maruishi
  October 2, 2018

• FDA OKs Pediatric Label Expansion for Fycompa: Eisai
  October 2, 2018

• Alnylam Files Patisiran in Japan, Anticipates Nod in Mid-2019
  October 2, 2018

• Astellas Seeks Approval for Japan’s 1st HIF-PH Inhibitor Roxadustat
  October 2, 2018

• Wholesalers See “Some Reduction in Yakkasa” in Price Negotiations under New Guidelines: Will Reduction Continue?
  October 2, 2018

• Maruho Licenses Cancer Stomatitis Treatment from NCC
  October 2, 2018

• Konica Minolta Embarks on Precision Medicine Biz, Ex-GSK/AZ Exec Takes Helm
  October 1, 2018

• 5 Years after Transparency Guidelines Rollout, R&D Costs Halve while Dining Outlays About to Disappear
  October 1, 2018

• Maruho Takes Over Differin Gel Marketing Authorization from Galderma
  October 1, 2018

• Vortioxetine Filed in Japan for MDD: Takeda/Lundbeck
  October 1, 2018

• Hisamitsu Files Transdermal Parkinson’s Disease Drug in Japan
  October 1, 2018

• 2 Camps of Biosimilar Makers Seek Japan Approval for Nesp Follow-Ons
  October 1, 2018

• Takeda Touts Progress in R&D Makeover, Departure from Small Molecules
  September 28, 2018

• Kyorin, Teijin Dissolve Capital Alliance
  September 28, 2018

• Alnylam Plants Flag in Japan Soil, Eyes 4 RNAi Therapeutic Launches in 5 Years
  September 28, 2018

• Number of Sales Reps in 43 Pharmas Dwindles by 4,906 in 4 Years: Survey
  September 28, 2018

• Daiichi Sankyo Begins PIII Breast Cancer Trials for DS-8201
  September 27, 2018

• IBM Japan Joins Takeda’s Shonan iPark
  September 27, 2018

• Celgene Seeks Japan OK for Pomalyst Triplet for MM
  September 27, 2018

• Alunbrig Outstrips Xalkori in Front-Line ALK NSCLC, Cuts Disease Progression or Death Risks by 51%: Takeda
  September 27, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 379
• 380
• 381
• 382
• 383
• 384
• 385
• 386
• 387
• …
• Next ›
• 最終 »